0OIR Annual Report 2022: Alk Delivers Sales Growth Of 13% With Profits Up 33% In 2022
February 03 2023 - 5:09AM
UK Regulatory
TIDMALK TIDMB
ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has
approved the company's 2022 annual report (ESEF-version
ALK-2022-12-31-en attached). Following a solid Q4, full-year
results exceeded initial expectations and were in line with the
most recent outlook. ALK expects to continue its trajectory of
growth and earnings improvement in 2023.
(Revenue growth rates are stated in local currencies.
Comparative figures for 2021 are shown in brackets)
Q4 2022 highlights
-- Revenue grew by 12% to an all-time high quarterly revenue of DKK 1,249
million (1,099).
-- EBITDA increased to DKK 201 million (136) on higher sales and
efficiencies.
Full-year 2022 highlights
-- Revenue increased by 13% to an all-time-high of DKK 4,511 million (3,916),
based on growth in all sales regions and across all product lines.
Reported growth was 15% when including the effect from exchange rate
fluctuations.
-- Tablet sales grew 18% on market expansion and market share gains, as
tablet sales accounted for 46% of total revenue (45). Sales of SCIT and
SLIT-drops were up 3%, while sales of other products increased 27%,
driven by the Jext(R) adrenaline auto-injector.
-- EBITDA was up 33% in DKK to a best-ever result of DKK 708 million (534),
driven by top-line growth, margin expansion and efficiencies. EBIT was up
61% in DKK to DKK 470 million (292).
-- Free cash flow was positive at DKK 65 million (202), mainly reflecting
higher earnings, changes to working capital and higher CAPEX investments.
2023 financial outlook
ALK expects sales growth across all regions and improved
profitability. From 2023, ALK will guide on EBIT margin instead of
EBITDA to align with its long-term financial ambitions.
-- Revenue is expected to grow 7-11% in local currencies, equalling 8-12%
growth when disregarding a one-year temporary mandatory rebate increase
of 5 percentage points for all prescription drugs in Germany.
-- Earnings will benefit from revenue growth, economies of scale and lower
R&D costs, despite tougher market conditions, including the effect of
cost inflation. The EBIT margin is expected at 13-15% vs. 10% in 2022.
ALK's CEO Carsten Hellmann says: "2022 was another year of
double-digit growth in revenue and earnings, and we also made solid
progress on our strategic agenda. We expect continued growth and
further earnings improvements in 2023, despite inarguably tougher
conditions, including a one-off rebate increase in Germany and
ongoing inflation. We are well prepared to deal with these
challenges. Our business platform and market positions are robust,
and the market transition is in our favour. We will continue to
execute on our strategy and push for improved results in the coming
years."
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This information is information that ALK-Abelló A/S is obliged
to make public pursuant to the EU Market Abuse Regulation.
Webcast
Today, ALK is hosting a conference call for analysts and
investors at 2.00pm (CET) at which Management will review the
financial results and the outlook. The conference call will be
audio cast on
https://www.globenewswire.com/Tracker?data=banVhodI4I8D0SUACU2IQn4Hn82irld3sU0Rsa_XEzJ13YF7_NlCOaxcqRff81-YvhZs7nSuHxbAA3_elN8xBMsV5VE8FWOJpEZ4eL0pHagwTIRKrSl135yp9wuV8SmoyxRIvsVSoLMxChyF3rKl7YQXVe7QaS2O7f3CL65u-xvzEmy9wP0JMGfhZnfWfQAJEB2br8JkJeNRJK9GiAuUrArpFlbaPThT5n1iqBGatow=
https://ir.alk.net where the accompanying presentation will be
available shortly before the call begins. Participants in the
conference call are kindly requested to call in before 1.55pm
(CET). Danish participants should call in on tel. +45 7877 4197 and
international participants should call in on tel. +44 0 808 101
1183 or +1 785 424 1739. Please use the following participant pin
code: 91630#
About ALK
ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK
employs around 2,700 people worldwide and is listed on Nasdaq
Copenhagen. Find more information at www.alk.net.
Attachments
-- FM_01_23UK_03022023_combined
https://ml-eu.globenewswire.com/Resource/Download/ea4f16db-19f3-45a3-9d4d-79408c5b7dc4
-- alk-2022-12-31-en
https://ml-eu.globenewswire.com/Resource/Download/764a9bc6-d080-4b37-96ec-304003dc5cdf
(END) Dow Jones Newswires
February 03, 2023 06:09 ET (11:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Apr 2024 to May 2024
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From May 2023 to May 2024